3.15
+12.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ARS Pharmaceuticals
From its filings with the US Securities and Exchange Commission
ARS Pharmaceuticals is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SPRY. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $84.3m and a net loss of $171.3m. At that date it held total assets of $327.7m and shareholders' equity of $114.3m.
We are a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (“EU”) and United Kingdom (“U.K.”) by the trade name EURneffy and in China by the trade name 优敏速) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is the first and only FDA and European Commission (“EC”)-approved needle-free epinephrine product, and also has approvals in the U.K., Japan, Australia, and China. It is the first new delivery method for epinephrine in more than 35 years. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions (including repeat dosing and allergen challenge).
We believe neffy’s “no needle, no injection” approach addresses a significant unmet need in the use of epinephrine. There are approximately 40 million people in the U.S. who experience Type I allergic reactions. Of this group, approximately 20 million people are reported to have been diagnosed and experienced severe Type I allergic reactions that may lead to anaphylaxis, and approximately 6.5 million of those were prescribed an epinephrine autoinjector. However, in recent years, only an estimated one-half of those consistently fill their prescribed autoinjector with them. We believe the market opportunity for neffy in the U.S. is significant.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Dec 2020
- Employees
- 158
- Website
- ars-pharma.com ↗
- Head office
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Pratik ShahChairman of the Board$542,932
- Mr. Richard LowenthalPresident, Chief Executive Officer, Director, since 2022$7.2m
- Ms. Kathleen ScottChief Financial Officer
- Mr. Brian DorseyChief Operating Officer$2.2m
- Mr. Justin ChakmaChief Business Officer
- Mr. Eric KarasChief Commercial Officer$222,624
- Dr. Sarina TanimotoChief Medical Officer$4.2m
- Mr. Alexander FitzpatrickSecretary and Chief Legal Officer$5.3m
- Mr. Brenton SaundersDirector$282,932
- Dr. Laura ShawverDirector, since 2022$272,932
- Dr. Rajeev DadooIndependent Director$282,932
- Mr. Saqib IslamIndependent Director$287,932
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 37
- Social
- 53
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ARS Pharmaceuticals has developed neffy, a novel intranasal epinephrine product for anaphylaxis treatment.
- The company focuses on a first-in-class product candidate with potential market leadership in emergency allergy treatment.
- ARS Pharmaceuticals employs 158 full-time employees, supporting robust clinical development efforts.
Weaknesses
- The company's product neffy is still in clinical development, requiring further regulatory approvals.
- ARS Pharmaceuticals has a small employee base of 158, limiting operational scale and resource allocation.
- The firm's IPO in December 2020 may indicate early-stage financial constraints.
Opportunities
- The growing market for anaphylaxis treatments presents significant expansion potential for neffy.
- ARS Pharmaceuticals can leverage its clinical development stage to attract strategic partnerships.
- The US biotechnology sector continues to show strong growth and investment opportunities.
Threats
- Regulatory delays could impact the commercialization timeline for neffy in the US market.
- Competition from existing epinephrine products may challenge neffy's market entry.
- The biotechnology industry faces high R&D costs and potential funding shortages.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.